Identification

Name
Nebivolol
Accession Number
DB04861
Type
Small Molecule
Groups
Approved, Investigational
Description

Nebivolol is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription. [Wikipedia]

Structure
Thumb
Synonyms
  • 1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
  • 1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
  • alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
  • alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
  • Narbivolol
  • Nebivololum
External IDs
PI-21858 / R65,824
Product Ingredients
IngredientUNIICASInChI Key
Nebivolol hydrochlorideJGS34J7L9I152520-56-4JWEXHQAEWHKGCW-VCVZPGOSSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BystolicTablet5 mg/1OralPhysicians Total Care, Inc.2008-10-02Not applicableUs00456 1405 01 nlmimage10 683a3461
BystolicTablet10 mg/1OralCardinal Health2008-01-22Not applicableUs00456 1410 01 nlmimage10 6d3a36a1
BystolicTablet10 mg/1OralA S Medication Solutions2008-01-222017-06-20Us
BystolicTablet20 mg/1OralCardinal Health2008-01-22Not applicableUs00456 1420 30 nlmimage10 44132249
BystolicTablet2.5 mgOralForest Laboratories2013-04-02Not applicableCanada
BystolicTablet5 mg/1OralAllergan2008-01-22Not applicableUs
BystolicTablet5 mg/1OralAvera Mc Kennan Hospital2015-03-19Not applicableUs
BystolicTablet10 mg/1OralPhysicians Total Care, Inc.2009-04-15Not applicableUs
BystolicTablet20.0 mgOralForest Laboratories2013-04-02Not applicableCanada
BystolicTablet5 mg/1OralA S Medication Solutions2008-01-222017-06-20Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NebivololTablet2.5 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet20 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet5 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet10 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
International/Other Brands
Lobivon / Nebicard / Nebilet / Nebilong / Nodon / Nubeta
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ByvalsonNebivolol hydrochloride (5 mg/1) + Valsartan (80 mg/1)Tablet, film coatedOralAllergan2016-06-03Not applicableUs
Categories
UNII
030Y90569U
CAS number
118457-14-0
Weight
Average: 405.435
Monoisotopic: 405.175164703
Chemical Formula
C22H25F2NO4
InChI Key
KOHIRBRYDXPAMZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
IUPAC Name
1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino}ethan-1-ol
SMILES
OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2

Pharmacology

Indication

For the treatment of essential hypertension.

Structured Indications
Pharmacodynamics

Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion.

Mechanism of action

Nebivolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

The absorption of nebivolol is rapid and not affected by food.

Volume of distribution
Not Available
Protein binding

98%

Metabolism

Hepatic (CYP2D6-mediated)

Route of elimination
Not Available
Half life

10 hours

Clearance
Not Available
Toxicity

The most common signs and symptoms associated with nebivolol overdosage are bradycardia and hypotension. Other important adverse events reported with nebivolol overdose include cardiac failure, dizziness, hypoglycemia, fatigue and vomiting. Other adverse events associated with β-blocker overdose include bronchospasm and heart block. The largest known ingestion of nebivolol worldwide involved a patient who ingested up to 500 mg of nebivolol along with several 100 mg tablets of acetylsalicylic acid in a suicide attempt. The patient experienced hyperhydrosis, pallor, depressed level of consciousness, hypokinesia, hypotension, sinus bradycardia, hypoglycemia, hypokalemia, respiratory failure and vomiting. The patient recovered.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nebivolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nebivolol.Experimental
AbirateroneThe serum concentration of Nebivolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nebivolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nebivolol.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nebivolol is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nebivolol.Approved, Withdrawn
AmbrisentanNebivolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateNebivolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineNebivolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nebivolol.Approved
AminophyllineNebivolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nebivolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nebivolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nebivolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nebivolol.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nebivolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nebivolol.Approved
ArbutamineNebivolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArformoterolNebivolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nebivolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nebivolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nebivolol.Approved, Investigational
ArtemetherThe serum concentration of Nebivolol can be increased when it is combined with Artemether.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nebivolol.Approved
AtomoxetineThe serum concentration of Nebivolol can be increased when it is combined with Atomoxetine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nebivolol is combined with Azilsartan medoxomil.Approved
BambuterolNebivolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Nebivolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Nebivolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nebivolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nebivolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nebivolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nebivolol.Withdrawn
Benzylpenicilloyl PolylysineNebivolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBepridil may increase the hypotensive activities of Nebivolol.Approved, Withdrawn
BeractantNebivolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe serum concentration of Nebivolol can be increased when it is combined with Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Nebivolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Nebivolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nebivolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nebivolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Nebivolol.Approved, Investigational
BQ-123Nebivolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Nebivolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nebivolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nebivolol.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nebivolol.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Nebivolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nebivolol.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Nebivolol.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nebivolol.Approved, Investigational
BupranololNebivolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe serum concentration of Nebivolol can be increased when it is combined with Bupropion.Approved
CabergolineCabergoline may increase the hypertensive activities of Nebivolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Nebivolol.Experimental
CafedrineNebivolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantNebivolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Nebivolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Nebivolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nebivolol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nebivolol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nebivolol.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nebivolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nebivolol.Approved, Investigational
CelecoxibThe serum concentration of Nebivolol can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololNebivolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibNebivolol may increase the bradycardic activities of Ceritinib.Approved
ChloroquineThe serum concentration of Nebivolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nebivolol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Nebivolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nebivolol.Approved
CholecalciferolThe serum concentration of Nebivolol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CicletanineNebivolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nebivolol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nebivolol.Approved, Investigational
CimetidineThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Nebivolol can be increased when it is combined with Cinacalcet.Approved
CitalopramThe serum concentration of Nebivolol can be increased when it is combined with Citalopram.Approved
ClemastineThe serum concentration of Nebivolol can be increased when it is combined with Clemastine.Approved
ClenbuterolNebivolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Nebivolol can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nebivolol.Approved, Investigational
ClomipramineThe serum concentration of Nebivolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nebivolol.Approved
CloranololNebivolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe serum concentration of Nebivolol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Nebivolol can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Nebivolol can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Nebivolol can be increased when it is combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nebivolol.Approved, Investigational
CrizotinibNebivolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nebivolol.Approved
CyclopenthiazideNebivolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Nebivolol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.Approved
DarifenacinThe serum concentration of Nebivolol can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nebivolol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Nebivolol.Approved, Investigational
DelaprilNebivolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Nebivolol can be increased when it is combined with Delavirdine.Approved
DeserpidineNebivolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nebivolol.Approved
DesipramineThe serum concentration of Nebivolol can be increased when it is combined with Desipramine.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Nebivolol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nebivolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nebivolol.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nebivolol.Approved
diethylnorspermineNebivolol may increase the hypotensive activities of diethylnorspermine.Investigational
DigoxinDigoxin may increase the bradycardic activities of Nebivolol.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Nebivolol.Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Nebivolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nebivolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.Approved
DiphenhydramineThe serum concentration of Nebivolol can be increased when it is combined with Diphenhydramine.Approved
DipivefrinNebivolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nebivolol.Approved
DobutamineNebivolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Nebivolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nebivolol.Approved
DosulepinThe serum concentration of Nebivolol can be increased when it is combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nebivolol.Approved
DronedaroneThe serum concentration of Nebivolol can be increased when it is combined with Dronedarone.Approved
DroxidopaNebivolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineThe serum concentration of Nebivolol can be increased when it is combined with Duloxetine.Approved
DyphyllineNebivolol may decrease the bronchodilatory activities of Dyphylline.Approved
EfonidipineNebivolol may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe serum concentration of Nebivolol can be increased when it is combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nebivolol.Approved, Vet Approved
EnalaprilatNebivolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nebivolol.Experimental
EpanololNebivolol may increase the hypotensive activities of Epanolol.Experimental
EphedraNebivolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineNebivolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nebivolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Nebivolol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nebivolol.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Nebivolol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Nebivolol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Nebivolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nebivolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nebivolol.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Nebivolol.Approved
FenoterolNebivolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
Ferulic acidNebivolol may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nebivolol.Approved, Investigational
FingolimodNebivolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FluoxetineThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolNebivolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nebivolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nebivolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Nebivolol.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Nebivolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nebivolol.Approved
GuanazodineNebivolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Nebivolol.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nebivolol.Approved, Investigational
GuanoclorNebivolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNebivolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNebivolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nebivolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nebivolol.Experimental
HexamethoniumNebivolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nebivolol.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nebivolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nebivolol.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nebivolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nebivolol.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nebivolol.Investigational
ImipramineThe serum concentration of Nebivolol can be increased when it is combined with Imipramine.Approved
IndacaterolNebivolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nebivolol.Approved
IndenololNebivolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nebivolol can be increased when it is combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Nebivolol.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nebivolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nebivolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nebivolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nebivolol.Approved
IsoetarineNebivolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nebivolol.Approved, Vet Approved
IsoniazidThe serum concentration of Nebivolol can be increased when it is combined with Isoniazid.Approved
IsoprenalineNebivolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nebivolol.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nebivolol.Approved
IvabradineNebivolol may increase the bradycardic activities of Ivabradine.Approved
KetanserinKetanserin may increase the hypotensive activities of Nebivolol.Investigational
KetoconazoleThe serum concentration of Nebivolol can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nebivolol.Approved
LacidipineNebivolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideNebivolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideNebivolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nebivolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nebivolol.Approved, Investigational
LevodopaNebivolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Nebivolol.Approved
LevosalbutamolNebivolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nebivolol.Approved, Investigational
LinsidomineNebivolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nebivolol.Approved, Investigational
LofexidineNebivolol may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Nebivolol can be increased when it is combined with Lopinavir.Approved
LorcaserinThe serum concentration of Nebivolol can be increased when it is combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nebivolol.Approved
LucinactantNebivolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumefantrineThe serum concentration of Nebivolol can be increased when it is combined with Lumefantrine.Approved
MacitentanNebivolol may increase the hypotensive activities of Macitentan.Approved
ManidipineThe serum concentration of Nebivolol can be increased when it is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nebivolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nebivolol.Approved
MethadoneThe serum concentration of Nebivolol can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nebivolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nebivolol.Approved
MethoserpidineNebivolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe serum concentration of Nebivolol can be increased when it is combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nebivolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nebivolol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Nebivolol.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nebivolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nebivolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol.Approved
MetoprololThe serum concentration of Nebivolol can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineNebivolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Nebivolol.Investigational, Withdrawn
MidostaurinThe serum concentration of Nebivolol can be increased when it is combined with Midostaurin.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Nebivolol.Approved
MinaprineMinaprine may increase the hypotensive activities of Nebivolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nebivolol.Approved
MirabegronThe serum concentration of Nebivolol can be increased when it is combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nebivolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Nebivolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nebivolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nebivolol.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nebivolol.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Nebivolol.Approved, Investigational
MuzolimineNebivolol may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nebivolol.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nebivolol.Approved
NaftopidilNebivolol may increase the hypotensive activities of Naftopidil.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nesiritide.Approved, Investigational
NevirapineThe serum concentration of Nebivolol can be increased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nebivolol.Withdrawn
NicardipineThe serum concentration of Nebivolol can be increased when it is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nebivolol.Approved
NiguldipineNebivolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nebivolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNebivolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nebivolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nebivolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nebivolol.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nebivolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nebivolol.Approved
NorepinephrineNebivolol may decrease the bronchodilatory activities of Norepinephrine.Approved
ObinutuzumabNebivolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nebivolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Nebivolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nebivolol.Approved, Investigational
OlodaterolNebivolol may decrease the bronchodilatory activities of Olodaterol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Nebivolol.Investigational
OrciprenalineNebivolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OxprenololOxprenolol may increase the hypotensive activities of Nebivolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nebivolol.Approved, Vet Approved
PanobinostatThe serum concentration of Nebivolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.Approved
PargylinePargyline may increase the hypotensive activities of Nebivolol.Approved
ParoxetineThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideNebivolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Nebivolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Nebivolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nebivolol.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nebivolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nebivolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nebivolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nebivolol.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nebivolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nebivolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nebivolol.Approved
PhenylpropanolamineNebivolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Nebivolol.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nebivolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nebivolol.Approved, Investigational
PirbuterolNebivolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Nebivolol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nebivolol.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Nebivolol.Approved
Poractant alfaNebivolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nebivolol.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nebivolol.Approved
PrimidonePrimidone may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ProcaterolNebivolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
PromazineThe serum concentration of Nebivolol can be increased when it is combined with Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the bradycardic activities of Nebivolol.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nebivolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nebivolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nebivolol.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nebivolol.Approved, Investigational
QuinidineThe serum concentration of Nebivolol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Nebivolol can be increased when it is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nebivolol.Approved
RanolazineThe serum concentration of Nebivolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Nebivolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nebivolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Nebivolol.Approved
RescinnamineNebivolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nebivolol.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nebivolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nebivolol is combined with Riociguat.Approved
RisperidoneNebivolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineNebivolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Nebivolol can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabNebivolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Nebivolol.Approved, Investigational
RolapitantThe serum concentration of Nebivolol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Nebivolol can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nebivolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nebivolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Nebivolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nebivolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Nebivolol.Withdrawn
SalbutamolNebivolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalmeterolNebivolol may decrease the bronchodilatory activities of Salmeterol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Nebivolol.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nebivolol.Approved, Investigational, Vet Approved
SelexipagNebivolol may increase the hypotensive activities of Selexipag.Approved
SertralineThe serum concentration of Nebivolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nebivolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Nebivolol.Approved
SitaxentanNebivolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Nebivolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nebivolol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Nebivolol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Nebivolol.Approved
StiripentolThe serum concentration of Nebivolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nebivolol.Approved, Investigational
SufentanilSufentanil may increase the bradycardic activities of Nebivolol.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
TalinololNebivolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Nebivolol.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nebivolol.Approved, Investigational
TemocaprilNebivolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Nebivolol.Approved
TerbinafineThe serum concentration of Nebivolol can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineNebivolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Nebivolol.Approved, Investigational
TetrahydropalmatineNebivolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nebivolol.Approved, Investigational, Withdrawn
TheodrenalineNebivolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineNebivolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ThioridazineThe serum concentration of Nebivolol can be increased when it is combined with Thioridazine.Approved, Withdrawn
TiboloneNebivolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe serum concentration of Nebivolol can be increased when it is combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Nebivolol.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nebivolol.Approved
TipranavirThe serum concentration of Nebivolol can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nebivolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Nebivolol.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nebivolol.Approved, Withdrawn
TolonidineNebivolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nebivolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nebivolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nebivolol.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nebivolol.Experimental
TranylcypromineThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nebivolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nebivolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nebivolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Nebivolol.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nebivolol.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
UnoprostoneNebivolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Nebivolol.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nebivolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nebivolol.Approved
VenlafaxineThe serum concentration of Nebivolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.Approved
VilanterolNebivolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineNebivolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNebivolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideNebivolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineNebivolol may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
ZiprasidoneThe serum concentration of Nebivolol can be increased when it is combined with Ziprasidone.Approved
ZofenoprilNebivolol may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Thomas Bader, Alfred Stutz, Harald Hofmeier, Hans-Ulrich Bichsel, "Process for preparation of racemic Nebivolol." U.S. Patent US20070149612, issued June 28, 2007.

US20070149612
General References
  1. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. [PubMed:16961165]
External Links
Human Metabolome Database
HMDB15594
KEGG Drug
D05127
PubChem Compound
71301
PubChem Substance
99443225
ChemSpider
64421
BindingDB
84735
ChEBI
64019
ChEMBL
CHEMBL434394
Therapeutic Targets Database
DAP000942
PharmGKB
PA151958426
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nebivolol
ATC Codes
C07FB12 — Nebivolol and other antihypertensivesC07AB12 — NebivololC07BB12 — Nebivolol and thiazides
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
MSDS
Download (69.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentCardiac Steatosis and Lipotoxicity1
1CompletedTreatmentHypertensive2
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentHypertensive2
2, 3CompletedPreventionDiabetes / Hypertensive1
2, 3WithdrawnHealth Services ResearchHigh Blood Pressure1
3Active Not RecruitingPreventionDuchenne's Muscular Dystrophy (DMD) / Heart Failure, Unspecified / Prophylaxis of cardiomyopathy1
3CompletedTreatmentHypertensive9
3CompletedTreatmentHypertensive / Peripheral Artery Disease (PAD)1
3CompletedTreatmentPrimary Arterial Hypertension1
3CompletedTreatmentStage 1 Hypertension / Stage 2 Hypertension1
3Unknown StatusTreatmentMarfan Syndrome1
4CompletedBasic ScienceMetabolic Syndromes1
4CompletedDiagnosticHypertensive2
4CompletedOtherHypertensive / Prehypertension2
4CompletedSupportive CareHypertensive1
4CompletedTreatmentAltitude / Arterial hypoxia / Heart Failure, Unspecified1
4CompletedTreatmentAtherosclerosis / Endothelial Function1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentCoronary Artery Disease / Hypertensive1
4CompletedTreatmentHigh Blood Pressure1
4CompletedTreatmentHypertensive12
4CompletedTreatmentHypertensive / Left Ventricular Diastolic Dysfunction1
4CompletedTreatmentHypertensive / Pre-Hypertension1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentMicrovascular Angina1
4CompletedTreatmentStage 2 Diastolic Hypertension1
4RecruitingPreventionBlood Pressures / Hypertension Complicated / Left Ventricular Hypertrophy1
4RecruitingTreatmentDiastolic Heart Failure / Heart Failure With Preserved Ejection Fraction (HFpEF) / Pulmonary Hypertension (PH)1
4TerminatedTreatmentCoronary Artery Disease1
4TerminatedTreatmentHypertensive2
4Unknown StatusTreatmentEndothelial Dysfunction / Hypertensive / Obstructive Sleep Apnea (OSA)1
4Unknown StatusTreatmentErectile Dysfunction (ED)1
4Unknown StatusTreatmentHypertensive1
Not AvailableActive Not RecruitingPreventionBone, Age-related / Osteoporosis, Age-Related1
Not AvailableActive Not RecruitingTreatmentHeart Failure, Unspecified1
Not AvailableCompletedNot AvailableHeart Failure, Unspecified / Hypertensive1
Not AvailableCompletedNot AvailableHypertensive / Multiple System Atrophy (MSA) / Progressive autonomic failure1
Not AvailableCompletedDiagnosticHypertensive1
Not AvailableCompletedTreatmentHypertensive2
Not AvailableRecruitingDiagnosticArterial Hypertension1
Not AvailableTerminatedTreatmentHypertensive1
Not AvailableTerminatedTreatmentHypertensive / Transplant; Failure, Kidney1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusNot AvailableHypertensive1
Not AvailableUnknown StatusTreatmentFemale Sexual Dysfunction (FSD) / Hypertensive1
Not AvailableWithdrawnTreatmentCentral Aortic Pressure1
Not AvailableWithdrawnTreatmentHypertensive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10.0 mg
TabletOral2.5 mg
TabletOral20.0 mg
TabletOral5.0 mg
Tablet, film coatedOral
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Bystolic 10 mg tablet2.09USD tablet
Bystolic 20 mg tablet2.09USD tablet
Bystolic 2.5 mg tablet2.06USD tablet
Bystolic 5 mg tablet2.06USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5759580No1995-06-022015-06-02Us
US6545040No2001-12-172021-12-17Us
US7803838No2006-08-292026-08-29Us
US7838552No2007-10-042027-10-04Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.44ALOGPS
logP3.21ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.52ChemAxon
pKa (Strongest Basic)8.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.32 m3·mol-1ChemAxon
Polarizability41.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8483
Blood Brain Barrier+0.7802
Caco-2 permeable-0.5549
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor INon-inhibitor0.7443
P-glycoprotein inhibitor IINon-inhibitor0.567
Renal organic cation transporterNon-inhibitor0.8016
CYP450 2C9 substrateNon-substrate0.8738
CYP450 2D6 substrateNon-substrate0.7248
CYP450 3A4 substrateNon-substrate0.6822
CYP450 1A2 substrateInhibitor0.5145
CYP450 2C9 inhibitorNon-inhibitor0.7876
CYP450 2D6 inhibitorNon-inhibitor0.5994
CYP450 2C19 inhibitorNon-inhibitor0.5923
CYP450 3A4 inhibitorNon-inhibitor0.9441
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8336
Ames testNon AMES toxic0.7132
CarcinogenicityNon-carcinogens0.9402
BiodegradationNot ready biodegradable0.9953
Rat acute toxicity2.7228 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5769
hERG inhibition (predictor II)Inhibitor0.8381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
1-benzopyrans
Alternative Parents
Aralkylamines / Alkyl aryl ethers / Benzenoids / Aryl fluorides / Secondary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Organopnictogen compounds / Organofluorides
show 1 more
Substituents
1-benzopyran / Alkyl aryl ether / Aralkylamine / Aryl fluoride / Aryl halide / Benzenoid / 1,2-aminoalcohol / Secondary alcohol / Oxacycle / Secondary amine
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, secondary alcohol, secondary amino compound, diol, chromanes (CHEBI:64019)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. [PubMed:16961165]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. de Boer RA, Voors AA, van Veldhuisen DJ: Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007 Jul;8(10):1539-50. [PubMed:17661735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Nuttall SL, Routledge HC, Kendall MJ: A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. [PubMed:12795776]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on October 19, 2007 15:00 / Updated on November 13, 2017 21:49